NCPI
NIH Cloud PlatformInteroperability Effort
searchclose
YouYube

Study

arrow_backDatasets

NHLBI TOPMed: TReating Children to Prevent EXacerbations of Asthma (TREXA)

phs001732.v1.p1dbGapdbGap FHIR

Description

TREXA is a 44-week randomized, double-blind, double-masked, four-treatment, parallel trial that will evaluate the weaning strategy that provides the best protection against the development of exacerbations in children whose asthma is acceptably controlled on a low dose of ICS (per NAEPP guidelines). Following the 4 weeks of the run-in period on a 1x dose of ICS (100 µg fluticasone b.i.d. or its equivalent), children who do not meet the definition of acceptable asthma control will be randomized to the parallel BADGER protocol; those who meet the definition of acceptable asthma control will be enrolled into the 44-week treatment phase of the study. The primary outcome measure will be time to first exacerbation requiring a prednisone course.

Summary

PlatformsBDC
Consent CodesDS-ASTHMA-IRB-COL
Focus / DiseasesAsthma
Study DesignProspective Longitudinal Cohort
Data TypesSNP/CNV Genotypes (NGS), WGS
Subjects89